| 臺大學術典藏 |
2021-02-18T02:09:13Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.;Wang S.-Y.;Lin S.-M.;Chen K.-Y.;Tseng J.-H.;Ho M.-C.;Lee R.-C.;Liang P.-C.;Liao L.-Y.;Huang K.-W.;Hu J.-T.;Liang J.-D.;Kee K.-M.;Lin C.-L.;Wang C.-K.;Lu S.-N.;Wang J.-H.;Lee W.-C.;Chen C.-H.;Liu C.-J.;Huang Y.-H.;Wang C.-C.;Wang T.-E.;Chuang P.-H.;Dai C.-Y.;Chiun Hsu;Chen S.-C.;Hsieh C.-H.;Diagnosis Group, Systemic Therapy Group; Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Chiun Hsu; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-02-18T02:09:13Z |
Corrigendum to Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Yau T.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Kang Y.-K.;Hou M.-M.;Numata K.;Yeo W.;Chopra A.;Ikeda M.;Kuromatsu R.;Moriguchi M.;Chao Y.;Zhao H.;Anderson J.;Dela Cruz C.;Kudo M.; Yau T.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Dela Cruz C.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.;Shao Y.-Y.;Chiun Hsu;Lee J.-M.;Yang M.-H.;Chao Y.; Hung Y.-P.; Shao Y.-Y.; Chiun Hsu; Lee J.-M.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Chiang N.-J.;Tsai K.K.;Hsiao C.-F.;Yang S.-H.;Hsiao H.-H.;Shen W.-C.;Chiun Hsu;Lin Y.-L.;Chen J.-S.;Shan Y.-S.;Chen L.-T.; Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; Yang S.-H.; Hsiao H.-H.; Shen W.-C.; Chiun Hsu; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
|
Yau T.;Kang Y.-K.;Kim T.-Y.;El-Khoueiry A.B.;Santoro A.;Sangro B.;Melero I.;Kudo M.;Hou M.-M.;Matilla A.;Tovoli F.;Knox J.J.;Ruth He A.;El-Rayes B.F.;Acosta-Rivera M.;Lim H.-Y.;Neely J.;Shen Y.;Wisniewski T.;Anderson J.;Chiun Hsu; Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; Chiun Hsu |
| 臺大學術典藏 |
2021-02-18T02:09:11Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
Cheng A.-L.;Chiun Hsu;Chan S.L.;Choo S.-P.;Kudo M.; Cheng A.-L.; Chiun Hsu; Chan S.L.; Choo S.-P.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
Pembrolizumab for the treatment of programmed death�Vligand 1?positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study
|
Mehnert J.M.;Bergsland E.;O??Neil B.H.;Santoro A.;Schellens J.H.M.;Cohen R.B.;Doi T.;Ott P.A.;Pishvaian M.J.;Puzanov I.;Aung K.L.;Chiun Hsu;Le Tourneau C.;Hollebecque A.;?Lez E.;Tamura K.;Gould M.;Yang P.;Stein K.;Piha-Paul S.A.; Mehnert J.M.; Bergsland E.; O��Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; Chiun Hsu; Le Tourneau C.; Hollebecque A.; ?lez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Lee M.S.;Ryoo B.-Y.;Numata K.;Stein S.;Verret W.;Hack S.P.;Spahn J.;Liu B.;Abdullah H.;Wang Y.;He A.R.;Lee K.-H.;Bang Y.-J.;Bendell J.;Chao Y.;Chen J.-S.;Chung H.C.;Davis S.L.;Dev A.;Gane E.;George B.;He A.R.;Hochster H.;Chiun Hsu;Ikeda M.;Lee J.;Lee M.;Mahipal A.;Manji G.;Morimoto M.;Numata K.;Pishvaian M.;Qin S.;Ryan D.;Ryoo B.-Y.;Sasahira N.;Stein S.;Strickler J.;Tebbutt N.; Lee M.S.; Ryoo B.-Y.; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; Chiun Hsu; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas
|
Chen M.-H.;Chou W.-C.;Hsiao C.-F.;Jiang S.S.;Tsai H.-J.;Liu Y.-C.;Chiun Hsu;Shan Y.-S.;Hung Y.-P.;Hsich C.-H.;Chiu C.-H.;Liu T.-C.;Cho S.-F.;Liu T.-W.;Chao Y.; Chen M.-H.; Chou W.-C.; Hsiao C.-F.; Jiang S.S.; Tsai H.-J.; Liu Y.-C.; Chiun Hsu; Shan Y.-S.; Hung Y.-P.; Hsich C.-H.; Chiu C.-H.; Liu T.-C.; Cho S.-F.; Liu T.-W.; Chao Y. |
| 臺大學術典藏 |
2021-02-18T01:45:21Z |
Novel systemic therapy for hepatocellular carcinoma
|
Dong Y.;Liu T.-H.;Yau T.;Chiun Hsu; Dong Y.; Liu T.-H.; Yau T.; Chiun Hsu |
